Over the past decade, peripheral blood progenitor cells (PBPCs) have replac
ed bone marrow as the major source of haematopoietic support. This transiti
on from marrow to PBPCs is due to the fact that, for many clinical studies,
a significantly faster rate of engraftment, particularly for platelets, ha
s been demonstrated for patients who receive PBPC support when compared to
similarly treated patients who are transplanted with bone marrow.
The leukapheresis procedure itself, quality of PBPC graft, methods of PBPC
mobilization, purging, and ex vivo expansion will be discussed in detail.